• About us
• Contact

Advertisement

Organisation › Details

MedImmune (biologics division of AstraZeneca)

MedImmune is the global biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres. *

 

	Start	1988-01-01 established_pre
	Group	AstraZeneca (Group)
	Predecessor	MedImmune Inc. (Nasdaq: MEDI)
	Industry	pharmaceutical
	Region	Gaithersburg, MD
	Country	United States (USA)
	Street	One MedImmune Way
	City	20878 Gaithersburg, MD
		Address record changed: 2020-12-02
Basic data	Employees	F: 1,001 to 5,000 (2005-05-14)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for AstraZeneca (Group)

• [1] Qiagen N.V.. (8/28/24). "Press Release: Qiagen Expands QIAstat-Dx into Precision Medicine through Partnership for Companion Diagnostics in Chronic Diseases". Venlo....
• [2] Pinetree Therapeutics, Inc.. (7/23/24). "Press Release: Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca". Cambridge, MA....
• [3] Huma Therapeutics Ltd.. (7/16/24). "Press Release: Huma Completes Series D with Total Financing of over $80m as It Launches Huma Cloud Platform with GenAI Integrations to Bring Digital First Care and Research to Everyone". London & New York, NY....
• [4] AstraZeneca plc. (3/19/24). "Press Release: AstraZeneca to Acquire Fusion to Accelerate the Development of Next-generation Radioconjugates to Treat Cancer"....
• [5] Amolyt Pharma SAS. (3/14/24). "Press Release: Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca. AstraZeneca Will Acquire Amolyt Pharma for up to $1.05 Billion in Total Consideration". Lyon & Cambridge, MA....
• [6] Allorion Therapeutics Inc.. (1/2/24). "Press Release: Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca". Natick, MA....
• [7] Gracell Biotechnologies Inc.. (12/26/23). "Press Release: Gracell Biotechnologies to Be Acquired by AstraZeneca, furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases". San Diego, CA, Suzhou & Shanghai....
• [8] AstraZeneca plc. (12/26/23). "Press Release: AstraZeneca to Acquire Gracell, Furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases"....
• [9] AstraZeneca plc. (12/12/23). "Press Release: AstraZeneca to Acquire Icosavax, Including Potential First-in-Class RSV and hMPV Combination Vaccine with Positive Phase II Data"....
• [10] Icosavax, Inc.. (12/12/23). "Press Release: Icosavax, Inc. Announces Agreement to Be Acquired by AstraZeneca". Seattle, WA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.